, PDF . " (http://vk.com/physimmun). . - 2014/2015 7 ? 22 2014 . , : 1. . . 2. . 3. - . 4. . . 5. . 6. , . 7. 8. 9. 10. . . . . MHC II MHC I . CD8, MHCI , CD4, MHCII IgG . , , IgM IgA IgE IgD , , . , . . . . . . YF-17D YF-17D , 7 15 4-6 18 30-40 . YF-17D (TLR2, 7, 8, 9, RIG-I, MDA5), . , IgM IgM , . B. IgG , CD8+ TCD4+ T- IgG , . , . 1 12-20 . , . IgM , IgG - , - , , )- . . IL-17 Th17 Th1 ROR t T-bet IFN STAT3 TGF , IL-6 , STAT4 IFN , IL-12 IL-21 IL-4 , Th0 IL-6 STAT3 Tfh Ascl2 TGF STAT5 TGF IL-10 IL-35 IL-4 STAT6 Treg Th2 FoxP3 GATA3 IL-4 IL-10 IL-13 anti-TGF R anti-STAT3 anti-ROR t anti-IL-17 IL-17 ROR t STAT3 TGF R . , . , . . , , . ( ) ( , ). , . . . , - , , • Aire • Fas / FasL • TGF , IL-10 • CTLA-4, PD-1 • FoxP3 • - - , : 1. ( , ) 2. ( , ) 3. , ) ( ( ), ). Th2 IFN IL-4, IL-10, - Th1 ). 0 + B H N- + I(0) II(A) III(B) IV( B) . , , , . - , BA B , - B1 . . B B , . B1 0 + + I(0) II(A) III(B) AB0 - IV( B) ( ). , . . , ( , ). MHCI, NK- . CD47. , " CD47 " . B H N- 0 I (0) H II ( ) A III ( ) B IV (AB) A, B -A, » 0 0 » : H-2b H-2k x -2b -2k -2b -2k F1(H-2b -2k) , , , , . MHC? MHCI (6 ). . TCR , MHCI, . TCR , MHCI, , . , . MHC - . MHC , ( ) , . , MHC . , . NFAT. , ( ) , : . . ? MDSC = myeloid-derived suppressor cells. , , . . " , , . Vesely et al, Annu Rev Immunol 2011, 29:235-271. • . , ( ( ) , ). • ( (MSI-H). ) , , . ). • ( ) . , . CTL / CD8+/FoxP3+ . Treg) • ( ). , . - , , . , . • ( ). , , TAA. • . , . • . : , . , 16 2.6 . , 15 1909 1910 , ( ) . , , RSV. (1894—1966) , . , . . . , – , . – , – , , , 17.01.1945 . - " ", . " ", : - ". 25% , 80% 80% 10% HPV = Human papillomavirus ( HBV, HCV = Human hepatitis B, C virus ( EBV = Epstein-Barr virus ( ) ) 10% ) 30% 2 20% 005. ) , Harald zur Hausen HPV HPV 100 HPV18, . , , HPV16 70% . HPV . , . 2011: anti-CTLA-4 Ipilimumab / MDX-010/101 / Yervoy (Bristol-Myers) 2014: anti-PD-1 James P. Allison, Ph.D Pembrolizumab / MK-3475 / Keytruda (Merck) Sipuleucel-T (Provenge) Prostatic specific acid phosphatase (PSAP) + Keyhole limpet hemocyanin (KLH) : : TLR . : " -" " : 1. . 2. ( ). 3. , , , ): , , : 5% . : 10 . 10%, . : 60 3 . -